Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lymphoma 161Leukemia 99Lymphoma, Large B-Cell, Diffuse 94Precursor Cell Lymphoblastic Leukemia-Lymphoma 92Lymphoma, Non-Hodgkin 91Leukemia, Myeloid, Acute 76Hodgkin Disease 73Lymphoma, Follicular 63Burkitt Lymphoma 60Lymphoma, Mantle-Cell 56Lymphoma, Large-Cell, Immunoblastic 55Small Cell Lung Carcinoma 46Leukemia, Lymphocytic, Chronic, B-Cell 42Lung Neoplasms 41Neuroblastoma 40Lymphoma, B-Cell, Marginal Zone 33Congenital Abnormalities 33Multiple Myeloma 30Recurrence 27Sarcoma 26Central Nervous System Neoplasms 26Carcinoma, Non-Small-Cell Lung 25Myelodysplastic Syndromes 24Leukemia, Myelomonocytic, Acute 24Leukemia, Monocytic, Acute 24Leukemia, Erythroblastic, Acute 24Testicular Neoplasms 22Lymphoma, Large-Cell, Anaplastic 22Leukemia, Megakaryoblastic, Acute 22Brain Neoplasms 22

Interventions

toripalimab 2sintilimab 2Surveys and Questionnaires 1Pemetrexed 1Paclitaxel 1Injections 1Etoposide 1Docetaxel 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Lung Cancer × Etoposide × Clear all
NCT05664971 2025-12-02

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Completed
119 enrolled
Thoracic

Advanced Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡